XML 76 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Business Segment Information [Text Block]

Note 2. BUSINESS SEGMENT INFORMATION

 

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief operating decision maker, the chief executive officer, for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

 

Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross sales to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross sales were as follows:

 2012 2011 2010
McKesson Corporation23% 26% 24%
Cardinal Health, Inc.19% 21% 21%
AmerisourceBergen Corporation14% 16% 16%

Selected geographic area information was as follows:

                        Net Sales                        Property, Plant and Equipment
Dollars in Millions2012 2011 2010 2012 2011
United States(a)$ 10,384 $ 14,039 $ 12,800 $ 4,464 $ 3,538
Europe(b)  3,706   3,879   3,672   740   886
Rest of the World(c)  3,204   3,237   2,900   129   97
Other(d)  327   89   112   -   -
Total$ 17,621 $ 21,244 $ 19,484 $ 5,333 $ 4,521

  • Includes Puerto Rico.
  • Includes Russia and Turkey.
  • Includes Japan, China, Canada, Australia and Brazil, among other countries.
  • Includes royalty-related revenues and sales attributed to supply agreements.

 

Net sales of key products were as follows:

  Year Ended December 31,
Dollars in Millions2012 2011 2010
Plavix* (clopidogrel bisulfate)$ 2,547 $ 7,087 $ 6,666
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)  503   952   1,176
Eliquis (apixaban)  2   -   -
Abilify* (aripiprazole)  2,827   2,758   2,565
Reyataz (atazanavir sulfate)  1,521   1,569   1,479
Sustiva (efavirenz) Franchise  1,527   1,485   1,368
Baraclude (entecavir)  1,388   1,196   931
Erbitux* (cetuximab)  702   691   662
Sprycel (dasatinib)  1,019   803   576
Yervoy (ipilimumab)  706   360   -
Orencia (abatacept)  1,176   917   733
Nulojix (belatacept)  11   3   -
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)  709   473   158
Byetta* (exenatide)  149  N/A  N/A
Bydureon*(exenatide extended-release for injectable suspension)  78  N/A  N/A
Mature Products and All Other  2,756   2,950   3,170
 Net Sales$ 17,621 $ 21,244 $ 19,484